CT Lung Screening Variation

Adoption of low-dose CT lung cancer screening is growing, and that’s a good thing. But rising LDCT utilization is also creating new challenges, illustrated by a new study in JACR that found high variability in radiologist interpretations. 

CT lung screening participation rates are rising, from single digits a decade ago to 19% in a recent survey

  • But there’s still a long way to go to get lung screening to the roughly 75% participation rate seen with breast cancer screening. 

One barrier to getting more people screened is false positives, which can cause patient anxiety and trigger a cascade of additional exams and procedures to work up suspicious findings. 

  • A major contributor to false positives may be variability in how radiologists read CT scans, so the JACR researchers investigated how interpretations for the same images changed between imaging specialists. 

Researchers looked at interpretations made by 1.4k radiologists, each of whom read a minimum of 50 LDCT screening exams (a total of 200k exams), then calculated false-positive rates for both baseline and follow-up exams. Researchers found…

  • High variability in false-positive rates, from 11% to 22%.
  • In random pairs of radiologists, on average, one radiologist would have twice the odds of making a false-positive call as the other. 
  • Radiologists with false-positive rates higher than the median rate also unsurprisingly had higher sensitivity than those below the median (97% vs. 92%).

What’s causing the variation? It could be because some radiologists use image interpretation patterns that increase false positives but also catch more cancers. 

  • In statistical terms, researchers found that for baseline screens read by radiologists who were below the median false-positive rate, they would have about 100 fewer false-positive screens for one fewer true-positive cancer. 

Radiologist variability could be reduced through programs to standardize screening interpretation, such as those implemented in mammography screening.

  • These could include support tools, automated feedback systems, educational interventions, and targeted double reading.

The Takeaway

The new findings on radiologist variability in reading CT lung cancer screening exams illustrate the delicate balance between detecting more cancer at the risk of producing additional false positives. Is the tradeoff worth it? We think we know how most patients would feel.

Two Views on Lung Screening’s Progress

Two new research studies published this week offer slightly conflicting views on the progress of CT lung cancer screening. One study saw the screening adherence rate rising to nearly 25%, while another revealed that screening might not be as effective in the real world as it was in the landmark National Lung Screening Trial. 

Low-dose CT lung cancer screening was approved for Medicare reimbursement in 2015 following promising NLST results, but the exam was slow to catch on.

  • That’s begun to change as U.S. physicians identify how to get eligible high-risk people into screening, while other countries are launching organized population-based screening programs, Germany being the most recent.

In the first study this week, published in JAMA Internal Medicine, researchers calculated the most recent uptake rate for LDCT lung cancer screening.

  • Data from 26.1k people from the BRFSS survey in 2024 were analyzed and compared to 2022 data.

The rate of up-to-date LDCT screening prevalence in 2024…

  • Rose six percentage points (24% vs. 18%).
  • Differed by just 0.5 percentage points between men and women.
  • Was highest and rose the most for people ages 65-69 (33%, increasing by 9 percentage points).
  • But still lagged screening rates for other cancers like breast (80%), cervical (75%), and colorectal (67%).

This week’s second study was published in JAMA Network Open and offers additional context, finding that real-world lung screening may not reduce all-cause mortality by as much as what was seen in the NLST.

  • Researchers analyzed screening’s effectiveness in a program run by the U.S. Veterans Health Administration, which has one of the more successful lung screening programs in the country.

They compared five-year all-cause mortality rates in the VA program for 732 people who were screened, finding that, compared to NLST…

  • Mortality rates were 2.5X higher in the VA population (24% vs. 9.7%).
  • VA participants had 3X the mortality risk (HR = 2.98).

VA researchers noted that while their population met the same screening eligibility criteria as NLST, the VA patients were sicker and probably less likely to see as much long-term benefit from LDCT screening.

The Takeaway

This week’s studies are a window into the complex changes underway in CT lung cancer screening. While screening’s rising participation rate is good news, the mortality findings show that estimating screening’s effectiveness is more complex than simply overlaying NLST results on real-world populations. 

Get every issue of The Imaging Wire, delivered right to your inbox.